Can a drug duo shrink inoperable lung tumors enough for surgery?

This trial is testing whether combining two drugs—an immunotherapy called adebrelimab and a targeted therapy called trastuzumab rezetecan—can shrink tumors in people with stage III HER2-positive lung cancer that cannot be removed surgically. Participants receive several cycles of the drug combination, then may undergo surgery or chemoradiation if the tumor shrinks enough. The goal is to see how well the treatment works at reducing tumor size and whether it helps people live longer without the cancer progressing.